Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
November 08, 2022 08:58 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational...
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
November 06, 2022 17:29 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of...
New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
November 05, 2022 10:35 ET
|
Lexicon Pharmaceuticals, Inc.
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that: Sotagliflozin...
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
November 04, 2022 08:58 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the...
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
October 31, 2022 08:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and...
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
October 24, 2022 08:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug...
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
October 02, 2022 13:00 ET
|
Lexicon Pharmaceuticals, Inc.
Data presented at the Heart Failure Society of America annual scientific meetingNew analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and...
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
September 20, 2022 08:59 ET
|
Lexicon Pharmaceuticals, Inc.
Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain Poster at International Association for the Study of Pain (IASP) World Congress on Pain Describing...
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
August 22, 2022 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies Recent Publication in the Journal Diabetes...
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
August 05, 2022 16:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the issuance and sale of an additional 2,526,540 shares of its common...